RYTM

Rhythm Pharmaceuticals' stock has been impacted by several key events over the past six months. The company reported strong Q4 2025 and Q1 2026 earnings, driven by IMCIVREE revenue and the U.S. launch for acquired hypothalamic obesity. IMCIVREE received FDA approval for acquired hypothalamic obesity and marketing authorization from the European Commission, expanding the company's addressable market. Analysts from Wells Fargo and RBC Capital maintained positive ratings and raised their price targets for RYTM following the Q1 2026 results. Investor reactions to previous earnings reports have been cautious.